PDCD1 and Miyoshi myopathy: For these reasons, the potential benefit of antibody blockade of the PD-1/PD-L1 pathway has been evaluated in patients affected by solid tumors such as renal cancer, melanoma, non-small cell lung cancer, and hematologic malignancies (e.g., Hodgkin Lymphoma and MM).